InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
Subscribe Login/Register
S&P 500
5,537.02
(
0.51%
)
US TECH 100
19,641.60
(
0.83%
)
Dow Jones
39,308.00
(
-0.06%
)
Brent Oil
86.69
(
-0.26%
)
Bitcoin
57,565.58
(
-4.32%
)
Post# of 252478
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 832
Posts 119978
Boards Moderated 17
Alias Born 09/05/2002

DewDiligence

Member Level

Re: jq1234 post# 165793

Wednesday, 08/28/2013 10:18:14 PM

Wednesday, August 28, 2013 10:18:14 PM

Post# of 252478

Never heard of EPIRUS until today.

They were founded in 2011 and they keep a pretty low profile. Their business model is clearly directed toward FoB’s in emerging markets, so I don’t see them as major competition for the MNTA/BAX partnership.

According to the company’s fact sheet (http://www.epirusbiopharma.com/files/130711%20-%20EPIRUS%20Fact%20Sheet%20(Final).pdf ), Epirus has FoB’s in preclinical development for Humira, Avastin, Herceptin, and Rituxan.

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up